First-in-Class Drugs against ocular diseases driven by hyper-vascularization and chronic inflammation Revolutionizing severe retinal disease care with topical therapy & saving lives with groundbreaking treatments for uveal melanoma Created in 2021 and located in Nice (France), Roca Therapeutics is a spin-off from Nice University and SATT Sud Est, incubated by the PACA-Est incubator. Roca has an internationally recognized team of Directors and Advisors with a strong track record of Translational Research and Drug Development in Oncology, Ophtalmology and Immunology. Roca Therapeutics is surrounded by several local and national strategic partners: IRCAN, ICN, Centre Antoine Lacassagne, CNRS, University Côte d’Azur, SATT Sud-Est, Canceropole PACA, Incubator Paca-Est, Eurobiomed, ... Roca Therapeutics has been rewarded by recognized prizes: i-Lab, bpifrance BFTE, PIA3, Amgen Prize, ... Roca Therapeutics is founded by a lead corporate VC and has been backed by several non-dilutive financings. In October 2022, Roca Therapeutics completes seed funding round. Our mission is to revolutionize eye care with innovative, non-invasive treatments, giving patients a brighter, clearer vision of life." title="" class="btn" data-container="body" data-html="true" data-id="179422" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="Roca Therapeutics"> 922
Activities
Technologies
Entity types
Location
112 Av. Sainte-Marguerite, 06200 Nice, France
Nice
France
Employees
Scale: 2-10
Estimated: 7
SIREN
898778188Engaged catalyst
11Added in Motherbase
2 years, 2 months agoA united team creating an innovative therapy to give a new life / vision to patients
First-in-Class Drugs against ocular diseases
driven by hyper-vascularization and chronic inflammation
Revolutionizing severe retinal disease care with topical therapy & saving lives with groundbreaking treatments for uveal melanoma
Created in 2021 and located in Nice (France), Roca Therapeutics is a spin-off from Nice University and SATT Sud Est, incubated by the PACA-Est incubator.
Roca has an internationally recognized team of Directors and Advisors with a strong track record of Translational Research and Drug Development in Oncology, Ophtalmology and Immunology.
Roca Therapeutics is surrounded by several local and national strategic partners: IRCAN, ICN, Centre Antoine Lacassagne, CNRS, University Côte d’Azur, SATT Sud-Est, Canceropole PACA, Incubator Paca-Est, Eurobiomed, ...
Roca Therapeutics has been rewarded by recognized prizes: i-Lab, bpifrance BFTE, PIA3, Amgen Prize, ...
Roca Therapeutics is founded by a lead corporate VC and has been backed by several non-dilutive financings.
In October 2022, Roca Therapeutics completes seed funding round.
Our mission is to revolutionize eye care with innovative, non-invasive treatments, giving patients a brighter, clearer vision of life.
Cancer treatment, Eye disease, Angiogenesis, Inflammation, Drug development, and Personalized therapy
A united team revolutionizing therapy to bring patients a new vision of life.
First-in-Class Drugs against ocular diseases
driven by hyper-vascularization and chronic inflammation
Revolutionizing severe retinal disease care with topical therapy & saving lives with groundbreaking treatments for uveal melanoma
Created in 2021 and located in Nice (France), Roca Therapeutics is a spin-off from Nice University and SATT Sud Est, incubated by the PACA-Est incubator.
Roca has an internationally recognized team of Directors and Advisors with a strong track record of Translational Research and Drug Development in Oncology, Ophtalmology and Immunology.
Roca Therapeutics is surrounded by several local and national strategic partners: IRCAN, ICN, Centre Antoine Lacassagne, CNRS, University Côte d’Azur, SATT Sud-Est, Canceropole PACA, Incubator Paca-Est, Eurobiomed, ...
Roca Therapeutics has been rewarded by recognized prizes: i-Lab, bpifrance BFTE, PIA3, Amgen Prize, ...
Roca Therapeutics is founded by a lead corporate VC and has been backed by several non-dilutive financings.
In October 2022, Roca Therapeutics completes seed funding round.
Our mission is to revolutionize eye care with innovative, non-invasive treatments, giving patients a brighter, clearer vision of life.
First-in-Class Drugs against ocular diseases driven by hyper-vascularization and immuno-suppressive inflammation.A united team creating an innovative therapy to give a new vision to patients.
Catalyst | Type | Tweets | Articles | |
---|---|---|---|---|
![]() La French Tech Côte d'Azur French Tech, IT Services and IT Consulting | La French Tech Côte d'Azur French Tech, IT Services and IT Consulting | Other 24 Sep 2024 | | |
![]() Inria Startup Studio Startup accelerator & VC | Inria Startup Studio Startup accelerator & VC | Other 13 Sep 2024 | | |
![]() CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 13 Sep 2024 | | |
![]() CEEI Nice Côte d'Azur Government Administration | CEEI Nice Côte d'Azur Government Administration | Other 3 Sep 2024 | | |
![]() Région Sud - Provence-Alpes-Côte d'Azur National and local authorities, Government Administration | Région Sud - Provence-Alpes-Côte d'Azur National and local authorities, Government Administration | Other 16 May 2024 | | |
![]() Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 26 Dec 2024 | | |
![]() Invest in Côte d'Azur - Team Nice Côte d'Azur Startup accelerator & VC, International Trade and Development | Invest in Côte d'Azur - Team Nice Côte d'Azur Startup accelerator & VC, International Trade and Development | Other 21 Jan 2025 | | |
![]() Métropole Nice Côte d'Azur Government Administration, French metropolis | Métropole Nice Côte d'Azur Government Administration, French metropolis | Other 26 Dec 2024 | | |
![]() CNRS Research, Research Services | CNRS Research, Research Services | Other 7 Dec 2024 | | |
![]() Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 26 Dec 2024 | |